Evidence map›Paper›PMID 35180851›Full record

ArticleBMC gastroenterology2022

Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study.

Tsung-Hsien Chiang, Yen-Nien Chen, Yi-Ru Chen, Yu-Hua Tseng, Chun-Fu Shieh, Cheng-Ying Liu, Han-Mo Chiu, Hung Chiang, Chia-Tung Shun, Ming-Shiang Wu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Tsung-Hsien ChiangDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yen-Nien ChenDepartment of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Yi-Ru ChenDepartment of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
Yu-Hua TsengLienchiang County Public Health Bureau, Nangan Township, Lienchiang County, Matsu, Taiwan.
Chun-Fu ShiehLienchiang County Hospital, Nangan Township, Lienchiang County, Matsu, Taiwan.
Cheng-Ying LiuLienchiang County Government, Nangan Township, Lienchiang County, Matsu, Taiwan.
Han-Mo ChiuDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Hung ChiangTaipei Institute of Pathology, Taipei, Taiwan.
Chia-Tung ShunDepartment and Graduate Institute of Forensic Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Ming-Shiang WuDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Jaw-Town LinDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yi-Chia LeeDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. yichialee@ntu.edu.tw.
National Taiwan University · TWChanghua County Public Health Bureau · TWMinistry of Health and Welfare · TWTaichung City Government · TWTaipei Institute of Pathology · TW

Funding

Minister of Science and Technology, R.O.C. 105-2314-B-002-069-MY3 and 108-2314-B-002-140-MY3National Taiwan University Hospital 110-P08
6 · The paper itself

Abstract

backgroundSerum pepsinogen (PG) is recommended as a screening test for premalignant gastric lesions. However, real-world evidence demonstrating its applicability and equivalence between different test brands is limited.

methodsMass screening began in 2018 in a high-risk Taiwanese population after eradication of Helicobacter pylori, with the first stage of two PG tests (GastroPanel

resultsAmong 7616 eligible participants, 5117 (67.2%) received PG tests and 284 (5.6%) tested positive. Of those who tested positive, 105 (37.0%) underwent endoscopy. Overall PPVs for atrophic gastritis and intestinal metaplasia were 12.4% and 18.9%, respectively, with detection rates of 2.5 and 3.9 per 1000, respectively. Correlations of numerical measures between tests were high and the agreements of test results were substantial. The PPVs (16.3% vs. 16.3% and 23.8% vs. 21.3%, P = 1.00 and 0.71, respectively), detection rates (2.5 vs. 2.5 and 3.7 vs. 3.3 per 1000, P = 1.00 and 0.27, respectively), and the stage distributions of gastritis were all comparable, which were confirmed by multiple regression analyses.

conclusionsPG testing is effective for mass screening after eradication of H. pylori. Tests from different manufacturers, even using different analytical methods and cutoff criteria, can perform equivalently.

Indexed as

GastritisGastritis, AtrophicHelicobacter InfectionsHelicobacter pyloriStomach NeoplasmsHumansPepsinogen APepsinogen CPepsinogen APepsinogen CDetection rateHelicobacter pyloriPepsinogenPositive predictive valueScreening

Identifiers

PMID35180851
PMCPMC8857789
OpenAlexW4213092882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.